Evidence for a causal role of ceramides in the liver to systemic metabolic dysfunction is given from obese animal models in which disruption of ceramide synthesis consistently prevented or reversed hepatic ceramide accumulation and improved insulin sensitivity, glucose tolerance, and hepatic steatosis [12, 29, 33, 217, 244–246, 252, 253]. Here, INS is linked to Hepatic steatosis.